<![CDATA[Pharmanovia 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=44015>Mon, 06 Apr 2026 00:55:39 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites]]>https://www.newswire.co.kr/newsRead.php?no=1001200Wed, 20 Nov 2024 15:30:00 +0900<![CDATA[파마노비아, 린디스 바이오텍과 신규 생물학적 제제 인라이선싱 계약 체결로 희귀 질환인 악성 복수 치료제 카투막소맙 상용화 추진]]>https://www.newswire.co.kr/newsRead.php?no=1001201Wed, 20 Nov 2024 15:30:00 +0900<![CDATA[Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio From Sanofi]]>https://www.newswire.co.kr/newsRead.php?no=974680Tue, 19 Sep 2023 10:10:00 +0900<![CDATA[파마노비아, 사노피로부터 중추신경계 글로벌 포트폴리오 인수]]>https://www.newswire.co.kr/newsRead.php?no=974681Tue, 19 Sep 2023 10:10:00 +0900